Show simple item record

dc.contributor.authorKumar, NPen_US
dc.contributor.authorVenkataraman, Aen_US
dc.contributor.authorNancy, Aen_US
dc.contributor.authorMoideen, Ken_US
dc.contributor.authorVaradarjan, Pen_US
dc.contributor.authorSelladurai, Een_US
dc.contributor.authorSangaralingam, Ten_US
dc.contributor.authorSelvam, Ren_US
dc.contributor.authorThimmaiah, Aen_US
dc.contributor.authorNatarajan, Sen_US
dc.contributor.authorRamasamy, Gen_US
dc.contributor.authorHissar, Sen_US
dc.contributor.authorRadayam Ranganathan, Uen_US
dc.contributor.authorBabu, Sen_US
dc.date.accessioned2023-01-03T16:39:24Z
dc.date.issued2022-09-28en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/83373
dc.description.abstractBACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) presents with inflammation and pathology of multiple organs in the pediatric population in the weeks following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. METHODS: We characterized the SARS-CoV-2 antigen-specific cytokine and chemokine responses in children with MIS-C, coronavirus disease 2019 (COVID-19), and other infectious diseases. RESULTS: MIS-C is characterized by elevated levels of type 1 (interferon-γ, interleukin [IL] 2), type 2 (IL-4, IL-13), type 17 (IL-17), and other proinflammatory cytokines (IL-1α, IL-6, IL-12p70, IL-18, and granulocyte-macrophage colony-stimulating factor) in comparison to COVID-19 and other infectious diseases following stimulation with SARS-CoV-2-specific antigens. Similarly, upon SARS-CoV-2 antigen stimulation, CCL2, CCL3, and CXCL10 chemokines were significantly elevated in children with MIS-C in comparison to the other 2 groups. Principal component analysis based on these cytokines and chemokines could clearly distinguish MIS-C from both COVID-19 and other infections. In addition, these responses were significantly diminished and normalized 6-9 months after recovery. CONCLUSIONS: Our data suggest that MIS-C is characterized by an enhanced production of cytokines and chemokines that may be associated with disease pathogenesis.en_US
dc.format.extent1215 - 1223en_US
dc.languageengen_US
dc.relation.ispartofJ Infect Disen_US
dc.subjectCOVID-19en_US
dc.subjectMIS-Cen_US
dc.subjectSARS-CoV-2en_US
dc.subjectchemokinesen_US
dc.subjectcytokinesen_US
dc.subjectin vitro cell cultureen_US
dc.subjectpediatric populationen_US
dc.subjectAntigens, Viralen_US
dc.subjectCOVID-19en_US
dc.subjectChemokinesen_US
dc.subjectChilden_US
dc.subjectCommunicable Diseasesen_US
dc.subjectCytokinesen_US
dc.subjectGranulocyte-Macrophage Colony-Stimulating Factoren_US
dc.subjectHumansen_US
dc.subjectImmunityen_US
dc.subjectInterferon-gammaen_US
dc.subjectInterleukin-13en_US
dc.subjectInterleukin-17en_US
dc.subjectInterleukin-18en_US
dc.subjectInterleukin-4en_US
dc.subjectInterleukin-6en_US
dc.subjectSARS-CoV-2en_US
dc.subjectSystemic Inflammatory Response Syndromeen_US
dc.titleEnhanced Severe Acute Respiratory Syndrome Coronavirus 2 Antigen-Specific Systemic Immune Responses in Multisystem Inflammatory Syndrome in Children and Reversal After Recovery.en_US
dc.typeArticle
dc.identifier.doi10.1093/infdis/jiac304en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35932220en_US
pubs.issue7en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume226en_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record